Global Antisense and RNAi Therapeutics Market 2015-2019

Global Antisense and RNAi Therapeutics Market 2015-2019 is a new market research publication announced by Reportstack. Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA. 

The analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79 percent over the period 2014-2019. This report covers the present scenario and the growth prospects of the Global Antisense and RNAi Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of antisense and RNAi therapeutics used for the treatment of various serious chronic diseases including:

• Infectious diseases

• Cardiovascular diseases

• Kidney diseases

• Cancer

• Metabolic disorders

• Others

The report also covers the two main technologies, i.e., Antisense and RNAi technology, which are used by vendors to develop antisense and RNAi therapeutics.

The report Global Antisense and RNAi Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Antisense and RNAi Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

• Americas

• APAC       

• EMEA

Key Vendors

• Alnylam Pharmaceuticals

• Isis Pharmaceuticals

• Sanofi

• Tekmira Pharmaceuticals

Other Prominent Vendors

 • Acuitas Therapeutics

• Allergan

• Antisense Therapeutics

• Ascletis

• AstraZeneca

• Atlantic Pharmaceuticals

• Benitec Biopharma

• Biogen Idec

• Bristol-Myers Squibb

• Dainippon Sumitomo Pharma

• Dicerna Pharmaceuticals

• Enzon Pharmaceuticals

• F. Hoffmann-La Roche

• Glaxosmithkline

• Gradalis

• iCo Therapeutics

• Kyowa Hakko Kirin

• Marina Biotech

• Novartis

• OncoGenex Pharmaceuticals

• OPKO Health

• Pfizer

• Quark Pharmaceuticals

• Regulus Therapeutics

• Silence Therapeutics

• Spectrum Pharmaceuticals

• Sylentis

• Takeda Pharmaceutical

• Teva Pharmaceutical

• The Medicines Company

• TransDerm 

Market Driver

• Advances in Technology

• For a full, detailed list, view our report

Market Challenge

• Toxicity of Antisense and RNAi Molecules-based Drugs

• For a full, detailed list, view our report

Market Trend

• Increased Strategic Collaborations and Licensing Activities

• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2018 and what will the growth rate be?

• What are the key market trends?

• What is driving this market?

• What are the challenges to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities and threats faced by the key vendors?

• What are the strengths and weaknesses of the key vendors?To view the table of contents and know more details please visit Global Antisense and RNAi Therapeutics Market 2015-2019